Everolimus is mainly used for the treatment of advanced renal cell carcinoma, pancreatic neuroendocrine tumors and other neoplastic diseases, and cannot be used for the treatment of duodenal adenocarcinoma.
Everolimus can inhibit the growth of solid tumors, and is used clinically in adult patients with advanced pancreatic neuroendocrine tumors, adult patients with advanced renal cell carcinoma who have failed previous sunitinib treatment, patients with subventricular giant cell astrocytomas that are unsuitable for surgical resection, and patients with renal angiomyosarcoma with lipoma of the kidney that requires treatment but does not require immediate surgery.
The most common adverse reactions to this product include stomatitis, rash, fatigue, diarrhea, infection, nausea, loss of appetite, anemia, taste disorders, and non-infectious pneumonitis, and it is contraindicated in patients who are allergic to this product.
Please use the medicine according to the doctor’s prescription after the doctor’s diagnosis first, do not blindly use the medicine by yourself to avoid delaying the condition.